WO1997041830A1 - Reparation and prevention of fibrotic lesions - Google Patents
Reparation and prevention of fibrotic lesions Download PDFInfo
- Publication number
- WO1997041830A1 WO1997041830A1 PCT/US1997/007468 US9707468W WO9741830A1 WO 1997041830 A1 WO1997041830 A1 WO 1997041830A1 US 9707468 W US9707468 W US 9707468W WO 9741830 A1 WO9741830 A1 WO 9741830A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyridone
- methyl
- phenyl
- group
- fibrotic
- Prior art date
Links
- 0 *C1C(*)=C(*)N(*)C(*)C1O Chemical compound *C1C(*)=C(*)N(*)C(*)C1O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12689197A IL126891A0 (en) | 1996-05-09 | 1997-05-03 | Reparation and prevention of fibrotic lesions |
CA002253919A CA2253919A1 (en) | 1996-05-09 | 1997-05-03 | Reparation and prevention of fibrotic lesions |
AU27519/97A AU725637B2 (en) | 1996-05-09 | 1997-05-03 | Reparation and prevention of fibrotic lesions |
JP09540064A JP2000510467A (en) | 1996-05-09 | 1997-05-03 | Repair and prevention of fibrotic lesions |
EP97921495A EP0902680A4 (en) | 1996-05-09 | 1997-05-03 | Reparation and prevention of fibrotic lesions |
NO985197A NO985197L (en) | 1996-05-09 | 1998-11-06 | Repair and prevention of fibrotic lesions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/647,006 US5716632A (en) | 1989-11-22 | 1996-05-09 | Compositions and methods for reparation and prevention of fibrotic lesions |
US08/647,006 | 1996-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997041830A1 true WO1997041830A1 (en) | 1997-11-13 |
Family
ID=24595333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/007468 WO1997041830A1 (en) | 1996-05-09 | 1997-05-03 | Reparation and prevention of fibrotic lesions |
Country Status (11)
Country | Link |
---|---|
US (1) | US5716632A (en) |
EP (1) | EP0902680A4 (en) |
JP (1) | JP2000510467A (en) |
KR (1) | KR20000010676A (en) |
AU (1) | AU725637B2 (en) |
CA (1) | CA2253919A1 (en) |
IL (1) | IL126891A0 (en) |
NO (1) | NO985197L (en) |
TR (1) | TR199802273T2 (en) |
WO (1) | WO1997041830A1 (en) |
ZA (1) | ZA974041B (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000016775A1 (en) * | 1998-09-18 | 2000-03-30 | Mepha Ag | Topical formulation of alkyl-, phenyl-pyridone |
EP1069898A1 (en) * | 1998-03-17 | 2001-01-24 | MARGOLIN, Solomon B. | Topical antiseptic compositions and methods |
WO2002060446A1 (en) * | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
WO2004073680A1 (en) * | 2003-02-21 | 2004-09-02 | Shionogi & Co., Ltd. | Ointment of droplet-dispersion type |
US7825133B2 (en) | 2003-11-14 | 2010-11-02 | Shanghai Genomics, Inc. | Derivatives of pyridone and the use of them |
EP2591784A1 (en) * | 2005-05-10 | 2013-05-15 | Intermune, Inc. | Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system |
EP2670242A1 (en) * | 2011-01-31 | 2013-12-11 | Genoa Pharmaceuticals, Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9029385B2 (en) | 2007-10-26 | 2015-05-12 | Ganesh Raghu | Compositions and methods for treating fibroproliferative disorders |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10188637B2 (en) | 2016-03-29 | 2019-01-29 | Hoffmann-La Roche Inc. | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962478A (en) * | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
AU784523B2 (en) * | 2000-01-24 | 2006-04-27 | Intermune, Inc. | Treatment of lymphomas, leukemias, breast carcinomas, astrocytomas, melanomas, leiomyomas, and related tumors |
DE10053870A1 (en) * | 2000-10-31 | 2002-05-08 | Burchardt Elmar Reinhold | Procollagen (III) propeptides and related substances for the treatment of fibrotic diseases |
WO2004019863A2 (en) * | 2002-08-28 | 2004-03-11 | Intermune, Inc. | Combination therapy for treatment of fibrotic disorders |
WO2005013917A2 (en) * | 2003-02-28 | 2005-02-17 | Intermune, Inc. | Combination therapy for treating alphavirus infection and liver fibrosis |
WO2004103296A2 (en) * | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
US20070172446A1 (en) | 2003-05-16 | 2007-07-26 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
DK1680137T3 (en) | 2003-10-14 | 2013-02-18 | Hoffmann La Roche | Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication |
US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
EP1789074A4 (en) * | 2004-08-09 | 2009-08-12 | Alios Biopharma Inc | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
CN1846699A (en) | 2005-04-13 | 2006-10-18 | 中南大学湘雅医院 | Application of 1-(substituted phenyl)-5-methyl-2-(1H)-pyridone compound in preparing medicine for anti-other organifibrosis and tissue fibrosis except renal interstitial fibrosis |
JP5249028B2 (en) | 2005-07-25 | 2013-07-31 | インターミューン・インコーポレーテッド | Novel macrocyclic inhibitor of hepatitis C virus replication |
NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
DE602006019323D1 (en) | 2005-10-11 | 2011-02-10 | Intermune Inc | COMPOUNDS AND METHOD FOR INHIBITING THE REPLICATION OF THE HEPATITIS C VIRUS |
WO2007047146A2 (en) * | 2005-10-11 | 2007-04-26 | Intermune, Inc. | Inhibitors of viral replication |
CN101460476B (en) * | 2006-06-05 | 2013-12-04 | 诺瓦提斯公司 | Organic compounds |
KR20090024834A (en) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Novel inhibitors of hepatitis c virus replication |
MX2009008439A (en) * | 2007-02-12 | 2009-08-13 | Intermune Inc | Novel inhibitors hepatitis c virus replication. |
CN101472588A (en) * | 2007-04-27 | 2009-07-01 | 达瑞科技投资有限公司 | Application of 5-methyl 1-(substituted phenyl group)-2-(1H) pyridinone compound as anti-inflammatory medicament and alpha-tumor necrosis factor (TNF-alpha) |
EP2177523A1 (en) | 2007-05-03 | 2010-04-21 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
JP2010526834A (en) * | 2007-05-10 | 2010-08-05 | インターミューン・インコーポレーテッド | Novel peptide inhibitors of hepatitis C virus replication |
MX2007009796A (en) * | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel containing pirfenidone. |
US8093210B2 (en) * | 2008-03-07 | 2012-01-10 | Solanan, Inc. | Treatment of sepsis with 5-ethyl-1-phenyl-2(1H)-pyridone |
EA201170441A1 (en) | 2008-10-15 | 2012-05-30 | Интермьюн, Инк. | THERAPEUTIC ANTI-VIRAL PEPTIDES |
US7566729B1 (en) | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
CN102292124A (en) * | 2009-01-26 | 2011-12-21 | 英特芒尼公司 | Methods for treating acute myocardial infarctions and associated disorders |
CN102149682B (en) | 2009-05-25 | 2012-12-05 | 中南大学 | Preparation methods and uses of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)-pyridone compounds and their salts |
KR101478133B1 (en) | 2009-05-25 | 2014-12-31 | 센트럴 사우스 유니버시티 | Preparation of 1-(substituted benzyl)-5-trifluoromethyl-2(1H)pyridone compounds and salts thereof and their applications |
CA2775697A1 (en) | 2009-09-28 | 2011-03-31 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis c virus replication |
WO2011054893A2 (en) | 2009-11-05 | 2011-05-12 | Novartis Ag | Biomarkers predictive of progression of fibrosis |
US8084475B2 (en) | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
WO2012107831A1 (en) | 2011-02-11 | 2012-08-16 | Signa S.A. De C.V. | Method of making a pyridone compound, 5-ethyl-1-phenyl-2-(1h)-pyridone, and intermediates thereof |
CA2819967C (en) * | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
NZ722927A (en) | 2014-01-10 | 2022-07-29 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
WO2018195338A1 (en) * | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
CN114716365B (en) * | 2022-01-04 | 2024-03-01 | 大连理工大学 | Application of N-substituted phenyl-2-pyridone compound or pharmaceutically acceptable salt thereof in treatment of pulmonary fibrosis |
CN114805333A (en) * | 2022-05-09 | 2022-07-29 | 大连理工大学 | Bismaleimide with main chain containing oxazine and Cardo structures and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5518729A (en) * | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1049411A (en) * | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
JPH02215719A (en) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | Agent for repairing fibrosing lesion tissue and preventing fibrosing lesion |
US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
ATE224712T1 (en) * | 1993-05-07 | 2002-10-15 | Solomon B Margolin | COMPOSITIONS AND METHODS FOR REPAIRING AND PREVENTING FIBROTIC INJURIES |
US5789426A (en) * | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
JPH11501911A (en) * | 1995-03-03 | 1999-02-16 | ビー マーゴリン、ソロモン | Treatment of diseases caused by cytokine growth factors |
EP0866656B1 (en) * | 1995-09-19 | 2007-04-25 | MARGOLIN, Solomon B. | Use of n-substituted pyridones as tumor necrosis factor alpha inhibitors |
-
1996
- 1996-05-09 US US08/647,006 patent/US5716632A/en not_active Expired - Lifetime
-
1997
- 1997-05-03 CA CA002253919A patent/CA2253919A1/en not_active Abandoned
- 1997-05-03 WO PCT/US1997/007468 patent/WO1997041830A1/en not_active Application Discontinuation
- 1997-05-03 IL IL12689197A patent/IL126891A0/en unknown
- 1997-05-03 EP EP97921495A patent/EP0902680A4/en not_active Withdrawn
- 1997-05-03 AU AU27519/97A patent/AU725637B2/en not_active Ceased
- 1997-05-03 KR KR1019980708678A patent/KR20000010676A/en not_active Application Discontinuation
- 1997-05-03 JP JP09540064A patent/JP2000510467A/en active Pending
- 1997-05-03 TR TR1998/02273T patent/TR199802273T2/en unknown
- 1997-05-09 ZA ZA974041A patent/ZA974041B/en unknown
-
1998
- 1998-11-06 NO NO985197A patent/NO985197L/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5518729A (en) * | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1069898A1 (en) * | 1998-03-17 | 2001-01-24 | MARGOLIN, Solomon B. | Topical antiseptic compositions and methods |
EP1069898A4 (en) * | 1998-03-17 | 2001-03-28 | Solomon B Margolin | Topical antiseptic compositions and methods |
US6492395B1 (en) | 1998-09-18 | 2002-12-10 | Mepha Ag | Topical formulation of alkyl-, phenyl-pyridone |
WO2000016775A1 (en) * | 1998-09-18 | 2000-03-30 | Mepha Ag | Topical formulation of alkyl-, phenyl-pyridone |
US9017722B2 (en) | 2001-01-29 | 2015-04-28 | Intermune, Inc. | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
WO2002060446A1 (en) * | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
US9561217B2 (en) | 2001-01-29 | 2017-02-07 | Intermune, Inc. | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
US7867516B2 (en) | 2001-01-29 | 2011-01-11 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
WO2004073680A1 (en) * | 2003-02-21 | 2004-09-02 | Shionogi & Co., Ltd. | Ointment of droplet-dispersion type |
US8084465B2 (en) | 2003-11-14 | 2011-12-27 | Shanghai Genomics, Inc. | Derivatives of pryidone and use thereof |
US8022087B2 (en) | 2003-11-14 | 2011-09-20 | Shangai Genomics, Inc. | Derivatives of pyridone and use thereof |
US7825133B2 (en) | 2003-11-14 | 2010-11-02 | Shanghai Genomics, Inc. | Derivatives of pyridone and the use of them |
EP2591784A1 (en) * | 2005-05-10 | 2013-05-15 | Intermune, Inc. | Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system |
US9527816B2 (en) | 2005-05-10 | 2016-12-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US10010536B2 (en) | 2005-05-10 | 2018-07-03 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US9029385B2 (en) | 2007-10-26 | 2015-05-12 | Ganesh Raghu | Compositions and methods for treating fibroproliferative disorders |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
USRE47142E1 (en) | 2008-06-03 | 2018-11-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9290450B2 (en) | 2008-06-03 | 2016-03-22 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
EP2670242A1 (en) * | 2011-01-31 | 2013-12-11 | Genoa Pharmaceuticals, Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
EP2670242A4 (en) * | 2011-01-31 | 2015-02-25 | Genoa Pharmaceuticals Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
EP4059499A1 (en) * | 2011-01-31 | 2022-09-21 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10376497B2 (en) | 2012-10-02 | 2019-08-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10898474B2 (en) | 2012-10-02 | 2021-01-26 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9675593B2 (en) | 2012-10-02 | 2017-06-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10544161B2 (en) | 2014-04-02 | 2020-01-28 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10188637B2 (en) | 2016-03-29 | 2019-01-29 | Hoffmann-La Roche Inc. | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Also Published As
Publication number | Publication date |
---|---|
EP0902680A4 (en) | 2000-04-19 |
EP0902680A1 (en) | 1999-03-24 |
CA2253919A1 (en) | 1997-11-13 |
IL126891A0 (en) | 1999-09-22 |
NO985197D0 (en) | 1998-11-06 |
NO985197L (en) | 1998-11-06 |
US5716632A (en) | 1998-02-10 |
TR199802273T2 (en) | 2000-11-21 |
KR20000010676A (en) | 2000-02-25 |
ZA974041B (en) | 1998-11-09 |
AU725637B2 (en) | 2000-10-19 |
JP2000510467A (en) | 2000-08-15 |
AU2751997A (en) | 1997-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5716632A (en) | Compositions and methods for reparation and prevention of fibrotic lesions | |
US5518729A (en) | Compositions and methods for reparation and prevention of fibrotic lesions | |
AU687816B2 (en) | Compositions and methods for reparation and prevention of fibrotic lesions | |
US5310562A (en) | Composition and method for reparation and prevention of fibrotic lesions | |
EP0458861B1 (en) | Composition for reparation and prevention of fibrotic lesions | |
US5643939A (en) | Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation | |
TW449473B (en) | Compositions for inhibition of the pathophysiologic actions in mammals of tumor necrosis factor-alpha | |
US5344829A (en) | Use of OB-101 to treat inflammation | |
US5604199A (en) | Method of treating fibrosis in skeletal muscle tissue | |
Velosa et al. | Benefits and risks of nonsteroidal antiinflammatory drugs in steroid-resistant nephrotic syndrome | |
Zabludowski et al. | A multi-centre comparative study between ramipril and enalapril in patients with mild to moderate essential hypertension | |
EP1581227B1 (en) | A method for treating renal failure | |
AU4786499A (en) | Method of treating pulmonary hypertension | |
WO1998051313A1 (en) | Remedies for dry eye | |
SK2502004A3 (en) | Medicament comprising darifenacin, for the reduction of urgency in patients suffering from overactive bladder | |
JP2003504396A (en) | New uses of macrolide compounds | |
JP2002138052A (en) | Itching curative medicine | |
Adisen et al. | Successful treatment of severe discoid lupus erythematosus with azathioprine: A case report | |
WO1997000072A1 (en) | Anti-inflammatory/analgetic composition | |
JP2003128554A (en) | Antipruritic drug | |
JPH0761930A (en) | Inhibitor of cancer metastasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1019980708678 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/009187 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2253919 Country of ref document: CA Ref document number: 2253919 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998/02273 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997921495 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997921495 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980708678 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997921495 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980708678 Country of ref document: KR |